A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Background: The standard sunitinib schedule to treat metastatic renal cell carcinoma (mRCC) is 4 weeks on/2 weeks off (4/2). However, some studies revealed intolerable adverse events (AEs) in patients on this schedule. An alternative schedule, 2 weeks on/1 week off (2/1), may overcome this issue. Th...

Full description

Bibliographic Details
Main Authors: Huan Deng, Meng Li, Qian Wu, Li Wang, Zhengdong Hong, Fengming Yi, Yiping Wei, Wenxiong Zhang
Format: Article
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Oncology
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00313/full